NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis
NASDAQ:NUTX - US67079U3068 - Common Stock
83.79 USD
-4.6 (-5.2%)
83.84 USD
+0.05 (+0.06%)
We assign a fundamental rating of 6 out of 10 to NUTX. NUTX was compared to 101 industry peers in the Health Care Providers & Services industry. NUTX has an average financial health and profitability rating. NUTX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make NUTX suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
In the past year NUTX was profitable.
In the past year NUTX had a positive cash flow from operations.
NUTX had negative earnings in 4 of the past 5 years.
In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
NUTX has a better Return On Assets (8.82%) than 93.07% of its industry peers.
Looking at the Return On Equity, with a value of 34.08%, NUTX belongs to the top of the industry, outperforming 95.05% of the companies in the same industry.
NUTX has a Return On Invested Capital of 30.54%. This is amongst the best in the industry. NUTX outperforms 99.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROIC | 30.54% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NUTX has a Profit Margin of 10.76%. This is amongst the best in the industry. NUTX outperforms 96.04% of its industry peers.
Looking at the Operating Margin, with a value of 33.39%, NUTX belongs to the top of the industry, outperforming 99.01% of the companies in the same industry.
The Gross Margin of NUTX (48.77%) is better than 75.25% of its industry peers.
NUTX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NUTX is creating value.
Compared to 1 year ago, NUTX has less shares outstanding
The number of shares outstanding for NUTX has been increased compared to 5 years ago.
Compared to 1 year ago, NUTX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 1.97 indicates that NUTX is not a great score, but indicates only limited risk for bankruptcy at the moment.
NUTX has a Altman-Z score (1.97) which is in line with its industry peers.
NUTX has a debt to FCF ratio of 4.45. This is a neutral value as NUTX would need 4.45 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.45, NUTX is in the better half of the industry, outperforming 76.24% of the companies in the same industry.
A Debt/Equity ratio of 1.46 is on the high side and indicates that NUTX has dependencies on debt financing.
NUTX has a Debt to Equity ratio of 1.46. This is in the lower half of the industry: NUTX underperforms 68.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 1.97 |
ROIC/WACC4.34
WACC7.03%
2.3 Liquidity
A Current Ratio of 2.27 indicates that NUTX has no problem at all paying its short term obligations.
NUTX has a Current ratio of 2.27. This is in the better half of the industry: NUTX outperforms 79.21% of its industry peers.
NUTX has a Quick Ratio of 2.26. This indicates that NUTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.26, NUTX is in the better half of the industry, outperforming 79.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 430.28% over the past year.
NUTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 141.25%.
NUTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 222.96% yearly.
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
3.2 Future
NUTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.68% yearly.
NUTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 59.82% yearly.
EPS Next Y-9.22%
EPS Next 2Y25.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year144.93%
Revenue Next 2Y59.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 7.05, the valuation of NUTX can be described as very cheap.
Based on the Price/Earnings ratio, NUTX is valued cheaper than 97.03% of the companies in the same industry.
When comparing the Price/Earnings ratio of NUTX to the average of the S&P500 Index (27.08), we can say NUTX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 6.08, the valuation of NUTX can be described as very cheap.
NUTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. NUTX is cheaper than 97.03% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of NUTX to the average of the S&P500 Index (22.72), we can say NUTX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.05 | ||
| Fwd PE | 6.08 |
4.2 Price Multiples
NUTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NUTX is cheaper than 99.01% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, NUTX is valued cheaply inside the industry as 92.08% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.71 | ||
| EV/EBITDA | 3.1 |
4.3 Compensation for Growth
NUTX has a very decent profitability rating, which may justify a higher PE ratio.
NUTX's earnings are expected to grow with 25.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.68%
EPS Next 3YN/A
5. Dividend
5.1 Amount
NUTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
83.79
-4.6 (-5.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners21.51%
Inst Owner Change60.68%
Ins Owners3.03%
Ins Owner Change0%
Market Cap465.87M
Analysts82.22
Price Target253.3 (202.3%)
Short Float %25.35%
Short Ratio3.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP19.83%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4474.63%
Min EPS beat(2)9.6%
Max EPS beat(2)8939.67%
EPS beat(4)3
Avg EPS beat(4)2105.75%
Min EPS beat(4)-602.61%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)143.87%
Min Revenue beat(2)76.42%
Max Revenue beat(2)211.33%
Revenue beat(4)4
Avg Revenue beat(4)75.65%
Min Revenue beat(4)5.5%
Max Revenue beat(4)211.33%
Revenue beat(8)5
Avg Revenue beat(8)36.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)28.23%
PT rev (3m)143.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-169.52%
EPS NY rev (1m)0%
EPS NY rev (3m)43.23%
Revenue NQ rev (1m)-5.47%
Revenue NQ rev (3m)-5.47%
Revenue NY rev (1m)-4.73%
Revenue NY rev (3m)60%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.05 | ||
| Fwd PE | 6.08 | ||
| P/S | 0.75 | ||
| P/FCF | 6.71 | ||
| P/OCF | 6.56 | ||
| P/B | 2.36 | ||
| P/tB | 2.77 | ||
| EV/EBITDA | 3.1 |
EPS(TTM)11.89
EY14.19%
EPS(NY)13.79
Fwd EY16.46%
FCF(TTM)12.49
FCFY14.9%
OCF(TTM)12.78
OCFY15.25%
SpS112.28
BVpS35.45
TBVpS30.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROCE | 35.61% | ||
| ROIC | 30.54% | ||
| ROICexc | 35.64% | ||
| ROICexgc | 37.81% | ||
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% | ||
| FCFM | 11.12% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 8.22% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 59.03 | ||
| Cash Conversion | 31.12% | ||
| Profit Quality | 103.36% | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 1.97 |
F-Score8
WACC7.03%
ROIC/WACC4.34
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
EPS Next Y-9.22%
EPS Next 2Y25.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
Revenue Next Year144.93%
Revenue Next 2Y59.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4652.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1011.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y98.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.51%
OCF growth 3YN/A
OCF growth 5YN/A